Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar... | May 25, 2023
United States Omid Hamid Georged Yancopoulos Ashley Buford Drug Administration Regeneron Approach To Cancer Research
Source: marketscreener.com